{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:37:02Z","timestamp":1777916222804,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T00:00:00Z","timestamp":1511481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"crossref","award":["104-EDN10"],"award-info":[{"award-number":["104-EDN10"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jfma.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T04:35:48Z","timestamp":1513312548000},"page":"915-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B"],"prefix":"10.1016","volume":"117","author":[{"given":"Cheng-Hao","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Shiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaw-Town","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2017.11.012_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.11.012_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2017.11.012_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","author":"Chen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2017.11.012_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","article-title":"Global control of hepatitis B virus infection","volume":"2","author":"Kao","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2017.11.012_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11373-007-9225-8","article-title":"Hepatitis B viral factors and clinical outcomes of chronic hepatitis B","volume":"15","author":"Lin","year":"2008","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jfma.2017.11.012_bib6","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J","article-title":"Hepatitis B virus. The major etiology of hepatocellular carcinoma","volume":"61","author":"Beasley","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2017.11.012_bib7","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2011.36.2335","article-title":"Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C","volume":"29","author":"Huang","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2017.11.012_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.11.012_bib9","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.11.012_bib10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.11.012_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2017.11.012_bib12","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.11.012_bib13","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.11.012_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos (t) ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2017.11.012_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2017.11.012_bib16","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM197406132902402","article-title":"Antibody to hepatitis B core antigen: a sensitive indicator of hepatitis B virus replication","volume":"290","author":"Hoofnagle","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.11.012_bib17","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197806222982502","article-title":"Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen","volume":"298","author":"Hoofnagle","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.11.012_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1128\/CVI.00457-09","article-title":"Novel double-antigen sandwich immunoassay for human hepatitis B core antibody","volume":"17","author":"Li","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jfma.2017.11.012_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmi.2014.10.002","article-title":"Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection","volume":"21","author":"Song","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jfma.2017.11.012_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos (t) ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2017.11.012_bib21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7150\/thno.10636","article-title":"Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon","volume":"5","author":"Hou","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.jfma.2017.11.012_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jvh.12626","article-title":"Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir","volume":"24","author":"Xu","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2017.11.012_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrgastro.2015.8","article-title":"Viral hepatitis: HBV cure \u2014 can we pin our hopes on immunotherapy?","volume":"12","author":"Yang","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2017.11.012_bib24","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.cgh.2016.03.024","article-title":"Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E Antigen\u2013negative patients","volume":"14","author":"Hsu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2017.11.012_bib25","doi-asserted-by":"crossref","first-page":"11063","DOI":"10.18632\/oncotarget.14323","article-title":"Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-na\u00efve patients with chronic hepatitis B","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jfma.2017.11.012_bib26","doi-asserted-by":"crossref","first-page":"e4422","DOI":"10.1097\/MD.0000000000004422","article-title":"Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-na\u00efve chronic hepatitis B patients","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2017.11.012_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment","volume":"61","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.11.012_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2010.10.016","article-title":"Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections","volume":"55","author":"Oliviero","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.11.012_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jmv.24067","article-title":"Direct role of antibody-secreting B cells in the severity of chronic hepatitis B","volume":"87","author":"Zgair","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2017.11.012_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B","volume":"41","author":"Chi","year":"2015","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461730462X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461730462X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T09:36:12Z","timestamp":1603532172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966461730462X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S092966461730462X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2017.11.012","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}